Q2 EPS Estimates for Cytokinetics Reduced by Leerink Partnrs

Cytokinetics, Incorporated (NASDAQ:CYTK) – Investment analysts at Leerink Partnrs lowered their Q2 2025 EPS estimates for shares of Cytokinetics in a research note issued on Wednesday, May 7th. Leerink Partnrs analyst R. Ruiz now expects that the biopharmaceutical company will post earnings of ($1.34) per share for the quarter, down from their prior forecast of ($1.32). The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. Leerink Partnrs also issued estimates for Cytokinetics’ Q3 2025 earnings at ($1.41) EPS, Q4 2025 earnings at ($1.58) EPS, FY2025 earnings at ($5.69) EPS, FY2026 earnings at ($5.25) EPS, FY2027 earnings at ($3.90) EPS and FY2028 earnings at ($0.95) EPS.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.36) EPS for the quarter, topping analysts’ consensus estimates of ($1.41) by $0.05. The company had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $2.77 million. During the same quarter in the previous year, the company earned ($1.33) EPS. The business’s quarterly revenue was up 89.1% compared to the same quarter last year.

CYTK has been the topic of a number of other reports. HC Wainwright reissued a “buy” rating and issued a $120.00 price target on shares of Cytokinetics in a report on Monday, April 21st. JMP Securities restated a “market outperform” rating and issued a $78.00 price target on shares of Cytokinetics in a research report on Thursday, April 10th. Citigroup reduced their target price on Cytokinetics from $86.00 to $80.00 and set a “buy” rating on the stock in a research note on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and set a $72.00 target price on shares of Cytokinetics in a research report on Friday, May 2nd. Finally, Barclays dropped their price objective on shares of Cytokinetics from $55.00 to $53.00 and set an “overweight” rating on the stock in a research note on Thursday. Three research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $74.44.

Cytokinetics Stock Down 2.4 %

Shares of CYTK stock opened at $31.69 on Friday. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28. The company’s fifty day moving average price is $40.18 and its 200-day moving average price is $45.96. The company has a market capitalization of $3.78 billion, a price-to-earnings ratio of -5.89 and a beta of 0.81. Cytokinetics has a one year low of $31.67 and a one year high of $63.46.

Institutional Trading of Cytokinetics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Jones Financial Companies Lllp boosted its holdings in Cytokinetics by 189.8% during the 4th quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 374 shares during the period. Centricity Wealth Management LLC acquired a new stake in shares of Cytokinetics in the 4th quarter valued at about $29,000. Fifth Third Bancorp raised its position in Cytokinetics by 42.2% in the 1st quarter. Fifth Third Bancorp now owns 981 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 291 shares during the last quarter. Parallel Advisors LLC grew its holdings in shares of Cytokinetics by 500.5% during the first quarter. Parallel Advisors LLC now owns 1,099 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 916 shares during the last quarter. Finally, GAMMA Investing LLC raised its stake in shares of Cytokinetics by 281.0% during the first quarter. GAMMA Investing LLC now owns 1,120 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 826 shares during the last quarter.

Insider Transactions at Cytokinetics

In other news, EVP Andrew Callos sold 3,341 shares of the company’s stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $43.27, for a total transaction of $144,565.07. Following the completion of the sale, the executive vice president now owns 64,434 shares of the company’s stock, valued at $2,788,059.18. This represents a 4.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Robert I. Blum sold 16,970 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $43.44, for a total value of $737,176.80. Following the completion of the sale, the chief executive officer now directly owns 364,181 shares of the company’s stock, valued at approximately $15,820,022.64. This represents a 4.45 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 95,362 shares of company stock worth $3,899,118 over the last three months. 2.70% of the stock is currently owned by insiders.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.